Frequency and Risk Factors of Acute Myeloid Leukemia

NCT ID: NCT05787951

Last Updated: 2023-03-28

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-05-01
• Study Completion Date: 2025-08-01

Brief Summary

1. to assess the frequency of acute myeloid leukemia at clinical Haematology unit of Assiute university hospital

2. to study correlations of known risk factors and if there are new risk factors participate in increasing frequency of acute myeloid leukemia

Detailed Description

Acute myeloid leukaemia (AML) is a rare heterogeneous disease comprising a group of hematopoietic neoplasms originating from the excessive clonal proliferation of myeloid pre- cursor cells [1]. Diagnosis of AML is based on morphological diagnosis with proliferation of blast cells ≥ 20% of bone marrow cells, flow cytometric analysis and cytogenetic abnormalities, including the t(8;21)(q22;q22), t(15;17) (q22;q12) and inv (16)(p13.1;q22) which are associated with longer remission and survival, while alterations of chromosomes 5, 7, complex karyotype and 11q23 are associated with poor response to therapy and shorter overall survival [2] The etiological agent and pathogenesis of AML are not entirely clear, only few AML cases can be accurately classified through traditional cellular morphological classification [3]It is the most common acute leukaemia in adults. It accounts for 1.3% of new cancer patients in the United States, in 2018[ 4] Some factors are well documented to increase the risk of some types of leukemia such as benzene exposure and ionizing radiation [5] increased frequency of acute myeloid leukemia has been noticed at Haematology unit so the aim of the study to assess the the frequency of acute myeloid leukemia and to evaluate the risk factors for it .

Conditions

Myeloid Leukemia

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Interventions

Bone marrow aspirite for diagnosis

Routine investigation of acute myeloid leukemia such as bone marrow aspirite for diagnosis ,cbc

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Adult Patients(above 18 years) diagnosed as acute myeloid leukemia according to WHO diagnostic criteria

Exclusion Criteria

• Patients with other types of leukemia

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Sanaa Ezzat Hussien

Sanaa Ezzat Hussien

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Sanaa Hussien

Role: CONTACT

Sanaaezzate212@gmail.com

00201023127310

Osama Ibrahim

Role: CONTACT

Oibrahiem@yahoo.com

References

Hwang SM. Classification of acute myeloid leukemia. Blood Res. 2020 Jul 31;55(S1):S1-S4. doi: 10.5045/br.2020.S001.

Reference Type: BACKGROUND

PMID: 32719169 (View on PubMed)

Other Identifiers

Risk factors of AML

Identifier Type: -

Identifier Source: org_study_id